NOTIFICATION
OF LATE FILING
(Check
one):
|
☐
Form 10-K
|
☐
Form 20-F
|
☐
Form 11-K
|
☒
Form 10-Q
|
☐
Form 10-D
|
|
☐
Form N-CEN
|
☐
Form N-CSR
|
|
|
|
|
|
|
|
|
For
Period Ended:
|
September
30, 2021
|
|
|
|
|
|
|
☐
Transition Report on Form 10-K
|
|
|
|
|
☐
Transition Report on Form 20-F
|
|
|
|
|
☐
Transition Report on Form 11-K
|
|
|
|
|
☐
Transition Report on Form 10-Q
|
|
|
|
|
|
|
|
For
the Transition Period Ended:
|
|
|
Read
Instructions (on back page) Before Preparing Form. Please Print or Type.
|
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
SAB
Biotherapeutics, Inc.
Full
Name of Registrant
Big
Cypress Acquisition Corp.
Former
Name if Applicable
2100
East 54th Street North
Address
of Principal Executive Office (Street and Number)
Sioux
Falls, SD 57104
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
|
(a)
|
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
☒
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
The
Registrant is unable to file its Form 10-Q for the quarter ended September 30, 2021 (the “Quarterly Report”) within the prescribed
time period without undue hardship and expense to the Registrant. The Registrant requires additional time because its independent registered
public accounting firm requires additional time to complete its review of the Registrant’s financial statements. The Registrant
anticipates that it will file the Quarterly Report no later than five days after its original prescribed due date as provided by Exchange
Act Rule 12b-25.
PART
IV — OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
Russell
Beyer
|
|
(605)
|
|
937-7229
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s).
|
☒
Yes ☐ No
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof?
|
☐
Yes ☒ No
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
SAB
Biotherapeutics, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date
11/15/2021
|
|
/s/
Russell Beyer
|
|
By:
|
Russell
Beyer
|
|
Title:
|
Chief
Financial Officer
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of
the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by
an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of
the registrant shall be filed with the form.
ATTENTION
|
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
|
Big Cypress Acquisition (NASDAQ:BCYP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Big Cypress Acquisition (NASDAQ:BCYP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024